MedPath

The Metabolic Response to Reduced Branched-chain Amino Acids in Humans

Not Applicable
Completed
Conditions
Diabetes
Obesity
Insulin Resistance
Interventions
Other: BCAD2
Other: Whey protein powder
Registration Number
NCT03239717
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

Branched-chain amino acids (BCAAs) are essential nutrients that the body obtains from proteins found in food, especially meat, diary products, and legumes. Data from rodent studies suggest that reduction of dietary BCAAs will promote fat mass loss and improved control of blood glucose. The purpose of this study is to test if reduction of dietary BCAAs without reducing calorie intake will lead to similar metabolic benefits in humans. Here the investigators test the feasibility of reducing dietary BCAAs using BCAA-free meal replacement beverages for two months.

Detailed Description

This study, which will be completed over three months, involves replacing two meals a day with meal replacement beverages for two months, with a one month follow-up visit. These beverages will be made up by subjects using either a complete protein powder or BCAD2, a BCAA-free medical food. Participants will complete food diaries at baseline and at one month intervals during the study, and compliance will be assessed via food diaries, weekly telephone contact, and measuring returned food powder.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
16
Inclusion Criteria
  1. Male between the age of 35 - 65
  2. BMI between 28 - 35 (mildly obese/overweight)
  3. Fasting glucose level of 101 - 125 mg/dL
  4. Able and willing to give written informed consent
  5. Stable weight (within 5 lbs. for at least 3 months)
  6. Not taking (or willing to cease taking) over the counter vitamin/mineral supplements
  7. Not planning to begin an exercise or diet program
Exclusion Criteria
  1. Female
  2. Outside required age range of 35 - 65
  3. BMI not within range of 28 - 35
  4. Fasting glucose not within range of 101 - 125 mg/dL
  5. Use of prescription medications for diabetes or weight-loss
  6. Use of and unwillingness to discontinue over the counter supplements (e.g. cinnamon, chromium, protein powders) or weight loss beverage or meal plans (e.g. SlimFast or Jenny Craig).
  7. Low baseline albumin or pre-albumin levels (below normal reference range)
  8. Significant anemia (Hemoglobin < 11 g/dL)
  9. Known bleeding disorder or platelet dysfunction
  10. Already eating a low protein diet (less than 14% total caloric intake from protein), as calculated from food diaries provided by subjects
  11. Participating in intensive exercise training program (high to moderate intensity exercise greater than 210 minutes per week) or planning to start new exercise program during study period.
  12. Significant co-morbidities (including kidney disease, liver disease, GI disease, cardiovascular disease, respiratory disease, malnutrition, substance abuse, psychiatric disease, or a diagnosed eating disorder).
  13. Planned smoking cessation or attempt at smoking cessation during study period
  14. Inability to tolerate meal replacement beverages due to palatability
  15. Recent weight loss (> 5 lbs within 3 months).
  16. Bariatric surgery, gastric banding or liposuction
  17. Current or past (within 1 year) use of illicit drugs
  18. Claustrophobia

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ExperimentalBCAD2Participants in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
Whey protein powderWhey protein powderParticipants in the Placebo Arm will replace two-thirds of participants dietary protein intake with meal replacement beverages utilizing a complete protein powder.
Primary Outcome Measures
NameTimeMethod
Reduction of BCAA intake3 months

The principle outcome of this study is to determine if replacing 2/3rds of the subjects baseline protein intake with BCAA-free meal replacement beverages are a feasible method of selectively reducing BCAA consumption. Our principle outcome is to reduce BCAA intake by 50% or more in the Experimental Arm (BCAD2) of the study as compared to baseline intake.

Secondary Outcome Measures
NameTimeMethod
HbA1c3 months

HbA1c in mmol/mol

Weight3 months

Weight in kg

Fat mass3 months

Fat mass in kg

BMI3 months

Weight in kg and height in meters will be combined to report BMI in kg/m\^2

Resting metabolic rate3 months

Resting metabolic rate in kcal/hour

Fasting blood glucose3 months

Fasting blood glucose in mg/dL

Insulin3 months

Insulin in ng/dL

Glucose tolerance3 months

Area under the curve in mg/dL/min

Trial Locations

Locations (1)

University of Wisconsin-Madison School of Medicine and Public Health

🇺🇸

Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath